24 May 2013
Keywords: cell, thera, xyotax, sees, strong, ph, iii
Article | 18 July 2005
US drugmaker Cell Therapeutics posted encouraging gender-specific Phase III results on its anticancer drug candidate Xyotax (paclitaxel
poliglumex), at the 11 ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
18 July 2005
23 May 2013
© 2013 thepharmaletter.com